BioMarin Pharmaceutical Inc. buy UBS Group AG
Start price
20.02.25
/
50%
€65.70
Target price
20.02.26
€108.05
Performance (%)
-25.13%
Price
15.08.25
€49.19
Summary
This prediction is currently active. The prediction for BioMarin Pharmaceutical Inc. disappoints with a performance of -25.13%. This prediction currently runs until 20.02.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
BioMarin Pharmaceutical Inc. | -0.102% | -0.102% |
iShares Core DAX® | 0.648% | 1.259% |
iShares Nasdaq 100 | -0.034% | 2.797% |
iShares Nikkei 225® | 2.445% | 9.854% |
iShares S&P 500 | 0.492% | 2.570% |
Comments by UBS_Group_AG for this prediction
In the thread BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $109.00 to $113.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Stopped prediction by UBS_Group_AG for BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€51.06
05.08.25
05.08.25
€98.62
05.08.26
05.08.26
-3.66%
15.08.25
15.08.25
BioMarin Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€62.34
30.10.24
30.10.24
€97.65
30.10.25
30.10.25
-21.09%
15.08.25
15.08.25